免费文献传递   相关文献

Effects of salvianolic acid B on lipid peroxidation and metalloproteinase-2activity in fibrotic liver in rat

丹酚酸B盐对大鼠纤维化肝组织脂质过氧化及其MMP-2活性的影响



全 文 :·
`<
·
234

5™6789G:;<ÏÐâ=G
Ÿ 
MMP2
¡¢ƒ¦§
*Ÿc
1,2,
 ¡¡
1,

1,
W1£
1,
P¤¥
1,3
(1
é¥!ª¬¤k HImDª% no­®¯

é¥
201203;
2
pqaª¤k HI⥪% !ª«

é¥
200433;
3
é¥1r!ªs«k
E
­®%

é¥
201203)

Žz
] 


?’234

5¦§89G:$ÏÐâ=GÓ
MMP2
¡¢ƒ:89Gùåæ

¡¢
:Wistar
67í
å¤>$á;

öñ;

234

5;Ӆ‚­;

ëNJ¨ó`Օ/ABÙæ:89Göñ

ì‚



Ü6

R

2
34

54C;Ӆ‚­™];©TöÀ ÈÀ ¹]

$á;Óöñ;67lEä!ˆø5û

Ü6

R
。HE
úÓ
ýKú#Ë:;<¤¢VHÓýKäu

=ږr/rG:ST
(ALT,AST,Alb,T.Bil)
Ó:;<
SOD
¡¢
、GSH
x!Ó
GST
¡¢

54û݋/:;<
Hyp
x!
,Westernblot
r/

ñýKYαSMAñc%ƒ。²ýR`‹r/:;<MMP2/9
ƒ¡¢

£¤

öñ67:$J²ˆýKäuÓ:89G

—J²ˆ:$%¤¢Z[VH

öñ67rG
TBil
x!
、ALT
Ó
AST
¡¢²ˆ_œ

rG
Alb
x!²ˆ•€

:;<
Hyp
x!
、αSMAÓIñýKñc、MMP2¡¢²ˆøé,GSHx!、SOD
Ó
GST
¡¢²ˆß

234

5Ӆ‚­²ˆ•%:89Göñ67ƒrG
ALT
û>Ó:;<
Hyp
x!

uæöñ6
7:;<ƒαSMAÓIñýKñc%ƒ,ë234B5ù²ˆ,(è«é:;< MMP2¡¢,øé SOD¡¢Ó GSHx
!

234

5‹¯ßöñ67rG
TBil
x!

àœ:;<
GST
¡¢

£V

¾š89G:$ƒÏÐâ=GZ[Óß:
;<
MMP2
¡¢Þ234

54C:89G­®ùåæ


‘
] 
:89G

234

5

ÏÐâ=G
;¨
ÐÚ°ñcR

…‚­

’w)(
] 20090911

“”„Q
] 
%<‘&¨ÚÛÜ
(30472047,30772869);^
P
9&úð8&ò®šZLÛÜ
(08XD14041);^
Pœs$-=&


/0.õ;ÛÜ
(E03008);^
P9Òú­–Á˜

•d}–
] 
ø£P



/0ü
,Tel:(021)513288888111,
13661406534,Fax:(021)51328500,Email:chenghai_liu@ ya
hoocomcn

}–¥¦
] 
,G™

º»

š]

â®ý $-,:89Gƒ/
0
,Tel:13764524798,Email:rena1995@sohucom
  
DEÓ¨,/0bs

$,Ÿ ¡¢£¤Œ
:89G%w$ŠJƒw+ÓA/bF¡

2
34

5
(salvianolicacidB,SalB)
Þ2›ƒâ®
û뢣¤Ò

›ÂFw/0,z‘£¤ŠJ²
ˆƒ™¢v::89Gù
[1],
½(bs‘£¤
ƒ:89GùåæÓuæ:^É$%
(hepatic
stelatecel,HSC)
¡GŸ $%=bGˆžª× β
(transforminggrowthfactorβ,TGFβ)kAb]äJ
²
[2]。
Ÿn/0V>
[3],
:89GÞ¬¥•Z[
§¥“

ÏÐâ=GÓ¨ÐÚ°ñcR
(metalo
proteinase,MMPs)
¡¢¾“ä¯]‹:;<òU’
UV

Œ
HSC
¡GŸ:89Gžø”£$]­®ù


Ÿ/0Ȟœ:;<ÏÐâ=GÓ
MMP2/9
¡¢“G

Cè²³234

5:89Gƒù
åæ

1 
0)
11 
‰
 
Ÿ¢
Wistar
67
42
0

GI

•­
(160±10)g,
_©$%&.^Pz{‰$O

Ò¯,A
:SCXK(
f
)20040003。
1J67£–©
^P$-,6z{‰$O

{o»

12 

 
NJ¨ó`Õ
(dimethylnitrosamine,
DMN),
_:8G£qªÇñ+í

rG:ST=
ږ

ËÝó×4רbzR
(alanineaminotransami
nase,ALT),
cñc
(albumin,Alb),
j)(Î
(total
bilirubin,TBil),
è_>8õ£ˆ‰qã/01

؞×4
(hydroxyproline,Hyp)
™]â

¤³+


Peptides
LM’â

?7šα>†PPÂñc(α
smoothmuscleactin,αSMA)Ãc‰•,DAKOLM
·17·
u
35
Cu

w
2010
n

o
                             
Vol.35,Issue 1
January,2010
’â

?7š

ñýKÃc‰•
,Sigma
LM’â

13 

 
234

5

¤×ñ
C36H30O16Mg,ԙ
¤×Ð!
742,
{­œ,@æ,LM*šàáæ7

+U
85%。
Ÿ‚­
(perindopril),
_J9~

‚
ü

æ,JKLM

2 
Š‹
21 
:89Göñæ7
 
›œFú½éë¾
C
[45],
ë
DMN10μg·kg-167•­ƒÚ!,•/
AB

ì‚



Ü6

R

1
14


22 
¤;Ӎ,
 
íå¤>$á;

0

öñ;
12
0

234

54C;
12
0

©TöÀ ÈÀ 
¹]234
B10mg·kg-1[6];
…‚­;
12
0

ŒÔ“.`¹]…‚­
5mg·kg-1[7],
Ú!èÔ
Å©
65kg
£šä•­!ƒ
10
O!

Ü6

R

23 
rG:ST/
 
« ‹/ó4רbz
R
(alanineaminotransferase,ALT);
‚‹/×¨
bzR
(aspartateaminotransferase,AST);
¡J3²
‹/rG
Alb
x!

­·‹/rGj)(Î
(totalbilirubin,TBil)
x!

î>8õ£ˆ‰qã
/01=ږ‚²gCc

24 
:;<ÏÐâ=G/
 
á
100mg
:;©
1mL
ˆø5û
,4℃
V

”O
(4℃,5000×g,
10min),
á^Gn

î]=ږ‚²/
SOD,GST
¡¢Ó
GSH
x!

25 
:;<
Hyp
x!/
 
›]
Jamal
 54û
݋
[8]。
Èá
100mg
a:;<
,4℃
V

é
12
mol·L-1HCl
©
105℃
ûÝ
18h,
âm

á
100μL
ûÝn
40℃
p

-.á
Hyp
(Wnâ
02~16μg
;>(W™]o

ëÕ

ën
02mL,
b n

x
25%
™NJ¨×¨J¯Y
273%
œë4ƒkóf
ën

“
,50℃
ûw
90min,
Îá
A558{,Zq(W


-^Š‹/ŽŸ
A558{,#®(W|…Zq
ŽŸ
Hyp
x!
,Hyp
x!ë
“mg·g-1(
:;<
)”
%
&

26 
:;<žøú
 
:;<$¢JÌÑôn


¢Ë£

ˆ£KU>
4μm,îIvf‹û,
NJ¯Ô²

¤pù
HE
ú

‚¥¤(ýKú

27 
:;<αSMA,IñýKñc%ƒ Lñc
]¥‹

á
100mg
:;1mL
;<VÑô
n
(20mmol·L-1
ëGv
,1% NonidetP40,01%
P
NÚ¨h4v
,50mmol·L-1
TרJÚ
,5mmol·
L-1
vNÕïv4
,1mmol·L-1
¯J¨u-¦
,1ⅹ
ñcRuæÚ

$V

/jñcx!

á
30μg
jñcx!ƒ°ÝnCc
10%SDSPAGE
“¢üý
Wi

`489ÎÒbz

‹Ï§Å¡Ç

¤p
Ó½k¢αSMA,IñýK•(eUè>1∶200)
¨ß

{|

xë©#â=G‰Rª\ƒuN•ù


“kAG«lU‰
(Pierce
LM

bl
,X
l£¬l

½ëZqåfþo_fþ¤³

/Õ
U{

ë-äñc]¥Ò¬lë
05%
PNÚ
¨h4v{‹


GAPDH
¨ß2ÿ

ù>=›
]

v€z{­Ù

*ë^œ-ŽŸ

28 
:;<
MMP2/9
¡¢
 
²ýRf‹

›œÔ
²Fú
[9]。
æ7
01%
²ý
8%SDSPAGE
üý

á
30μgjñcCcMK@蓢Wi。üý‹
n

­{
、¨
ßëœÕd®húnú
,¯
ˆ&

MMP2/9
Ä©h¯¡^ƒÔ®ò

—òCc
fþ¤³

/ ÕU{

%
MMP2/9
ƒ¡¢

v€z{­Ù

*ë^œ-ŽŸ

29 
‡Z5ø
 
Z!¡)ë 珋x±s%&。L
EXCEL
“Œ˜‡Z5ø

;`‚ƒLÃªÎŠ
j¤³
,q
r{

3 
´—
31 SalB
™:89G67ôwþƒ¦§
 

;67•­ÏÏøé

¡ÂM

nbl®

öñ;
67•­øéљ

¡Âƒ€

nXl°
。SalB
;
YŸ‚­;67¡ÂÉÃA

•­

:

•‚

#

•‚Óöñ;ԂX²ˆjk

Tö´‡.ö
ñ;ӟ‚­;mH‰67

0

%
1)。
%
1 SalB
™67ôwþƒ¦§
(珋x±s)
;p

•­
/g
:•‚
/%
#•‚
/%

6 21933±1407 280±019 025±002
öñ
11 12309±10261) 163±0451) 049±0161)
SalB 12 1285±761 188±042 052±017
…‚­
11 11645±557 194±021 055±010
  
A

Ó$á;‚ƒ
1)P<005。
32 SalB
™:89G67:$¤qÓýKäuƒ¦
§
 
$á67:?þ´µÓ:$%”ä¥

öñ;
67:;<
HE
úJs[r±

:$%6!VH

½ñ6ƒ89`ìá

VH±=6!¤¢$%€
´

‚¥¤(ú¯JýK896!øˆäu

ӣ
ñ6‹·ƒDoR

$F&E89`ìŸ=?þ

½(
:²RýKäu²ˆ
。SalB
;Ӆ‚­;:$%
“¢²ˆ•%

ªJ±ÉVH

Jxˆ:$%

DoR
·27·
u
35
Cu

w
2010
n

o
                             
Vol.35,Issue 1
January,2010
J€B¤q$%€´

:?þ]¤l¤³
;SalB
; ¤qÓýKäu•%ãU©…‚­;

f
1)。
A
$á;
;B
öñ;
;CSalB
;
;D
…‚­;

f
1 SalB
™öñ67:;<ýKäuƒ¦§
(×200)
33 SalB
™:89G67rG:STƒ¦§
 
ö
ñ;67rG
ALT
Ó
AST
û>
、TBil
x!ˆ§œ©
$á67
,Alb
²ˆ©$á67
(P<005)。SalB
;Ӆ‚­;
ALT,AST
J1ß

rG
Alb
x!
øé

Óöñ;ԂXˆ§jk
;SalB
Ӆ‚­²
ˆßöñ67rG
TBil
x!
(P<005,
%
2)。
%
2 SalB
™:89Göñ67rG:STŸ
Hyp
x!ƒ¦§
(珋x±s)
;p
n ALT/U·L-1 AST/U·L-1 Alb/g·L-1 TBil/μmol·L-1 :;<Hyp/mg·g-1

6 5290±1768 7040±2180 3443±621 1835±712 2491±640
öñ
11 45891±106971) 40980±71331) 2077±3931) 5317±18711) 6464±16061)
SalB 12 31619±182012) 35728±12467 2241±701 3884±15432) 4989±15702)
…‚­
11 29643±170052) 33600±17385 2402±635 2579±7012) 5214±11002)
  
A

Ó$á;‚ƒ
1)P<005;
Óöñ;‚ƒ
2)P<005(
%

-
)。
34 SalB
™:89G67:;<

ñýKñc
Ó:;<
Hyp
x!ƒ¦§
 
Ó$á67‚ƒ

ö
ñ67:;<
Hyp
x!ˆ§øé
(P<005);
Ó
öñ;67‚ƒ
,SalB
;Ӆ‚­;:;<
Hyp
x!²ˆ«ß
(P<005),
 $ë
SalB
;
«ß²ˆ

%
2)。
Westernblot´
—ˆ&

$á67:;<€!%
ƒ

ñýKñc

öñ67:;<

ñýKñcˆ
§œ%ƒ

Óöñ;‚ƒ
,SalB
;Ӆ‚­;²
ˆ«é

ñýKñc%ƒ

(
SalB
;𩅂­
;

f
2)。
1
$á;
;2
öñ;
;3SalB
;
;4
…‚­;

f

-
)。
f
2 SalB
™67:;<αSMAÓIñýK
ñc%ƒƒ¦§
35 SalB
™:89G67:;< αSMAñc%
ƒƒ¦§
 Westernblot
ˆ&

$á67:;<€!
m«“œ%ƒαSMAñc,öñ;67:;<=6
!%ƒ αSMAñc;SalB;Ӆ‚­;²ˆ«
éαSMAñcƒ%ƒ,( SalB;𩅂­;

f
2)。
36 SalB
™:89G67:;<ÏÐâ=GZ[
ƒ¦§
 
öñ67:;<
SOD
Ó
GST
¡¢
、GSH
x!ˆ§©$á;
(P<005),
Óöñ;Ԃ
,Sal

Ӆ‚­²ˆøé:;<
SOD
¡¢Ó
GSH
x
!

(
SalB
ˆ§øé
GST
¡¢

%
3)。
%
3 SalB
™:89Göñ67:;<ÏÐâ
=GZ[ƒ¦§
(珋x±s)
;p
n SOD/U·g-1 GSH/mg·g-1 GST/U·g-1

6 2845±760 521±185 83±15
öñ
11 1230±5261) 277±291) 62±101)
SalB 12 2295±7882) 475±1062) 76±082)
…‚­
11 2196±7132) 419±992) 71±09
37 SalB
™:89G67:;<
MMP2/9
¡¢
ƒ¦§
 
²ýRf‹ˆ&

$á67:;<
MMP
2/9
¡¢ƒ

öñ;67:;<
MMP2/9
¡¢
·37·
u
35
Cu

w
2010
n

o
                             
Vol.35,Issue 1
January,2010
ˆ§_œ

  Þ
MMP2
_œƒ²ˆ

Óöñ;‚
ƒ
,SalB
Ӆ‚­ˆ§«é
MMP2
¡¢
(P<
005)。

MMP9
¡¢Œöñ;Ó,‰;Ò`“G
œ²ˆ

f
3)。
f
3 SalB
™67:;<
MMP2/9
¡¢ƒ¦§
4 
’
:89GÞ:;<™:$™¢EFƒžø½Ù
“

:;<$%ƒ¤¢Z[ZyyÞ:89G
ƒFwžø

Ÿz{L¾Aƒ:89G67ö
ñ
[3],
bs
SalB
²ˆ•%:;<¤¢Z[ÓýK
89äu

¾šöñ67rG:ST

ß89G:
;<ƒ
Hyp
x!

x,zë
SalB
ŠJAƒ
:Z[ӝ:89G+—

…‚­>ro2äÎ
bGRuæÚ
(ACEI),
Ÿn…,zJAƒ89
Gù
[10],
z{$ù>™],‰

|ŠJƒ¾
š:STùÓAƒ:89G+—

:;<ÏÐâ=G

â®bˆŒ:$%

œ;
}›Ó:Z[

|ޙ¢:Z[ã:89Gbðƒ
žøuv
[11],
È:89Gžøbˆƒ­®U®

Ï
Ðâ=GÞQŒ{¨ƒ´Ï«

$%œ‚Yϵ
4bˆâ=G“

ýˆ£†Å¡¢=ƒâã

:$%ƒÏÐâ=Gœ˜P$%==G‰Ð

M
SOD,GSH
ä

UV:$%´µ
,¯
ž]:$%R
ž¤q“

EFð‚¶$%¡Gä

( â=G
’‰M
MDA
ä¯;}EF
HSC
¡G

ZC89G

SOD
ޕ=GVõ=å”א{¨ƒâ®R†‡

Eâ,G“

TGV
O-·2 ä{¨,ýgh$%
´µYST
。GSH
ù>¬¤×GVÚ

VëT
;}-{¨“

M¯ù>
GST
Ÿ
GSHPx
ä
GSH
Ô²RƒU‰

|Þ啭®ƒ=G‰
Ð
[12]。
Fú`øÓ>yz{èbs
DMN
$Þ:8
9GöñJ²ˆƒ:;<ÏÐâ=G

(:;<ƒ
ÏÐâ=GÓ89GãUˆ§Ô²
[13]。
Ÿz{b
s
,DMN
\]ƒ:89G67:;<
SOD,GST
¡
¢Ó
GSH
x!²ˆ«ß

αSMA,IñýK%ƒ²
ˆøé

ôx,zë‘öñ:;<ÏÐâ=GZ

HSC
¡GÓ:89G

,‰;
SalB
Ӆ‚
­uæαSMA,IñýK%ƒ,àœ:89G67:
$
SOD
Ó
GST
¡¢
、GSH
x!

à&
SalB
Ӆ
‚­JAƒ:$â=GZ[ù

(ô¬ù
Þ
SalB
Ӆ‚­uæ
HSC
¡G

C%:89G
”£ƒ­®åæÒ

:89Gƒžøˆø½±ÈŒ©:;<ƒýK
ä$%¨Ð‘»?


MMPs
ŒýK‘$]
­®ù
。MMPs
J

¬­®ƒ#ñ
:`
ТýK
R

²ýR

ë¨ÐÎ
[14],
 STùJ1œ-

MMP2/9
  Þ
MMP2
Þ­®ƒ²ýR
,MMP2
¡¢øéÞ89Gžøbˆƒ­®Kª

/0b
s
[15],
Œ89Gà$w ð
,MMP2
ñcÓ¡¢6
!øé

ß
IV
ýKä

UV:²¨UÒ´µ

ô
¬;<òU’ƒ“G

œ.T:²¨UÒ$
IV
ñ
ýKäŠJ²+É´µƒýK•€

>‹·¢ƒ

ñýK1·

ZC”£:²n$roG

(

{©:²Rž¨Ð

$%U’ƒ¾“
,¯
ZC
HSC
¡G
[16]。
:;<
MMP2
…C©ð‚¶$%

=_
$%Ó
HSC
ä

 ¡¢øé­®KªVë
TGFβE
F

¡¢=Ÿ ÏÐâ=G|Þ­®ªÎ

Ÿ/0
bs89G:;<
MMP2
¡¢²ˆ_œ

,‰;
SalB
Ӆ‚­ˆ§uæ
MMP2
j•ñÓ¡¢
ñ

  ë
SalB
ù²ˆ

à&
SalB

MMP2
¡¢

gh:;<òU’Þuæ
HSC
¡G

4C:
89Gƒ¢­®ùåæ


—˜™š

[1] LiuP,HuYY,LiuC,etalClinicalobservationofsalvianolic
acidBinthetreatmentofliverfibrosisinchronichepatitisB[J].
WorldJGastroenterol,2002,8:679
[2] 
ø£P

ø>

Vù¸

ä

234

5™bGˆžª×β1
EF:^É$%¡GÓ%=kAb]ƒù
[J].
$/-
23
,2002,82(18):1267
[3] FriedmanSL,RockeyDC,BisselDMHepaticfibrosis2006:
reportofthethirdAASLDsingletopicconference[J].Hepatolo
gy,2007,45:242
[4] AlakokkoL,PihlajaniemiT,MyersJ,etalGeneexpressionof
typeI,IIandⅣ colagensinhepaticfibrosisinducedbydime
thylnitrosamineintherat[J]BiochemJ,1987,244:75
[5] 
,G™

ø£P

¬¾AƒNJ¨ó`Õ:89Göñ]Š‹Ÿ žø½±
[J]
$%z{‰`
,2007,15
(2):90
[6] 
Vù¸

ø>

ø£

ä

2›à቙
CCl4Y DMN\]
ƒ67:89Gƒ¦§
[J]^
P$-,23
,1999,10:7
·47·
u
35
Cu

w
2010
n

o
                             
Vol.35,Issue 1
January,2010
[7] 
¹ùº

¾2?

Û»‚

ä

…‚­Y¼Þq™:89
G67
TGFβ1Ÿ Iñæ• mRNAÓ Smad3,Smad7ƒ%
ƒƒ¦§
[J]
$/:$ž23
,2004,12(12):737
[8] JamalIS,FineliVN,QueHeeSSAsimplemethodtodeter
minenanogramlevelsof4hydroxyprolineinbiologicaltissues
[J].AnalBiochem,1981,112(1):70
[9] K1einerDE,StetlerStevensonWGQuantitativezymography:
Detectionofpicogranquantitiesofgelatinases[J]AnalBio
chem,1994,218:325
[10] 
#|

½¾

oþá

ä

…‚­z{¢67:89G
ƒz{/0
[J]
$/:$ž23
,2004,12(1):32
[11] BedossaP,HouglumK,TrautweinC,etalStimulationofcola
genalpha1(I)geneexpressionisassociatedwithlipidperoxida
tioninhepatocelularinjury:Alinktotissuefibrosis[J].Hepa
tology,1994,19(5):1262
[12] BrockR,ShirinH,AeedH,etalPreventionofhepaticcirho
sisinratsbyhydroxylradicalscavengers[J]JHepatol,2001,
35(4):457
[13] 
ø£P

ñFi

ø>

ä

$/:$ž23NJ¨ó`Õ
‹67ÏÐâ=G“GÓ,‰24ù
[J]
$/:$ž2
3
,2001(
øa
):18
[14] 


ø£

ø£P

¨ÐÚ°ñcRÓ:89Gƒ/0

[J]
%-
·
—G†©ž¤û
,2003,23(1):37
[15] LeeHS,HuangGT,ChenCH,etalLessreversalofliverfi
brosisafterprolongedcarbontetrachlorideinjection[J]Hepato
Gastroenterol,2001,48(41):1312
[16] GaliA,SvegliatiBaroniG,CeniE,etalOxidativestressstim
ulatesproliferationandinvasivenessofhepaticstelatecelsviaa
MMP2mediatedmechanism[J]Hepatology,2005,41:1074
EfectsofsalvianolicacidBonlipidperoxidationandmetaloproteinase2
activityinfibroticliverinrat
WANGLina1,2,TAOYanyan1,LIShu1,CHENGaofeng1,LIUChenghai1,3
(1LiverDiseaseInstitute,ShanghaiUniversityofTraditionalChineseMedicine,ShuguangHospital,Shanghai201203,China;
2DepartmentofChineseMedicine,SecondMilitaryMedicalUniversity,ChanghaiHospital,Shanghai200433,China;
3ExperimentalCenterofScienceandTechnology,ShanghaiUniversityofTraditionalChineseMedicine,Shanghai201203,China)
[Abstract] Objective:ToinvestigatethemechanismofsalvianolicacidB(SalB)actionagainstliverfibrosisthroughpreven
tinglipidperoxidationandregulatingMMP2activityinliverMethod:Theliverfibroticmodelwasinducedthroughintraperitonealy
injectionofDMNatadoseof10μg·kg-1foreveryotherdayandlastingfor4weeksSalBwasadministered(10mg·kg-1),and
perindopril(5mg·kg-1)wasusedaspositivecontrolHepaticinflammationandcolagenwereobservedwithHEandsiriusredstai
ningTheliverfunctionincludingserumALT,ASTactivity,Albandtotalbilirubin(TBil)levelweredeterminedThehepaticlipid
peroxidationincludingSODandGSTactivitiesandGSHcontentweremeasuredHepatichydroxyproline(Hyp)contentwasdetected
withJamal'smethodTheactivityofmetaloproteinasewasassayedbygelatinzymographyTheexpressionsofαSMA,ColIinliver
tissuewereanalyzedbyWesternblotResult:ThemodelratshadhigherserumTBilcontent,ALTandASTactivitiesbutlowerAlb
contentthanthenormalrats,alsohadremarkableinflammatorynecrosisandcolagendepositioninliver,withmuchhigherHypcon
tent,proteinexpressionofαSMAandcolagenIandMMP2activityinliver,buthadadecreasedGSHcontent,SODandGSTactivi
tiesBothSalBandperindoprilatenuatedhepaticinjuryandcolagendepositioninmodelrats,decreasedserumALTactivityandhe
paticHypcontent,downregulatedαSMAandcolagenIproteinexpressionsandmetaloproteinase2activitythanthoseinthemodel
group,butincreasedSODactivityandGSHcontent,andSalBdecreasedserumTBilcontentandincreasedGSTactivitySalBhad
amuchbetercomprehensiveactionsthanperindoprilConclusion:SalBhasagoodpreventiveactionagainstliverfibrosis,theaction
mechanismisrelatedtothepreventionfromlipidperoxidationanddownregulationofmetaloproteinase2activityinfibroticliver
[Keywords] salvianolicacidB;livercirhosis;lipidperoxide;metaloproteinase;perindopril
doi:10.4268/cjcmm20100115

›œ-0
 
¿ÀÀ

·57·
u
35
Cu

w
2010
n

o
                             
Vol.35,Issue 1
January,2010